hydroxychloroquine - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.09 [0.98, 1.21]< 10%11 studies (11/-)5.5 %some concernlow moderatecrucial-
deaths (time to event analysis only) 1.10 [0.99, 1.23]< 10%2 studies (2/-)3.9 %some concernnot evaluable moderatecrucial-
clinical deterioration 1.07 [0.62, 1.85]< 125%2 studies (2/-)40.7 %some concernnot evaluable moderateimportant-
clinical improvement 1.02 [0.73, 1.42]> 10%1 study (1/-)54.6 %lownot evaluable highimportant-
clinical improvement (14-day) 0.99 [0.72, 1.37]> 10%2 studies (2/-)47.9 %some concernnot evaluable moderateimportant-
death or ventilation 1.13 [1.03, 1.24]< 10%4 studies (4/-)0.6 %some concernnot evaluable moderateimportant-
hospital discharge 1.38 [0.46, 4.16]> 10%1 study (1/-)71.4 %some concernnot evaluable moderateimportant-
viral clearance 0.46 [0.04, 5.75]> 10%1 study (1/-)27.7 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.42 [0.26, 7.76]> 10%1 study (1/-)65.5 %some concernnot evaluable moderateimportant-
ICU admission 0.83 [0.35, 1.95]< 10%1 study (1/-)66.8 %some concernnot evaluable moderatenon important-

safety endpoints 00

cardiac arrest 1.92 [0.35, 10.49]< 10%1 study (1/-)22.7 %some concernnot evaluable moderateimportant-
adverse events 1.29 [0.98, 1.69]< 10%5 studies (5/-)3.4 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.